Fortrea Holdings Inc. (FTRE)
NASDAQ: FTREHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 20.56 0.00%
FTRE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.96B
- Forward P/E
- 17.96
- EPS (TTM)
- -$0.91
- Dividend yield
- None
- 52-week range
- 8.55 – 23.51
- Day range
- 20.24 – 21.11
- Volume / Avg
- 2.10M / 1.45M
- Beta
- —
- Shares outstanding
- 95.10M
- Next earnings
- Oct 29, 2026
52-week range
FTRE stock today
Fortrea (FTRE) closed at $20.56 on Oct 7, down 1.06% (-$0.22), versus the S&P 500's 0.22% decline. Shares are 12.5% below their 52-week high of $23.51, set on Oct 6, 2026 and 140.5% above the 52-week low of $8.55, near the top of the past year's range. FTRE is up 19.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 120.8%.
Fortrea has posted a net loss over the last twelve months (EPS of -$0.91), so its P/E ratio is not meaningful. Fortrea's next earnings report is expected on Oct 29, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Fortrea
Company profileFortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Anshul Thakral
- Headquarters
- Durham, NC
- Employees
- 14,000
- Website
- fortrea.com
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$20.83+1.31%
- Strong buy 1
- Buy 5
- Hold 5
- Sell 0
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $0.23
FTRE news
All FTRE newsFortrea peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALHCAlignment Healthcare Inc. | 8.55 | +2.15% | $1.77B | vs FTRE |
| FRNMFreenome Inc. | 16.03 | -2.02% | $1.72B | vs FTRE |
| PSNLPersonalis Inc. | 16.00 | -0.19% | $1.71B | vs FTRE |
| CLOVClover Health Investments Corp. Class A | 4.56 | -0.87% | $2.42B | vs FTRE |
| ACHCAcadia Healthcare Company Inc. | 29.23 | +0.65% | $2.72B | vs FTRE |
| TRUPTrupanion Inc. | 24.63 | -0.20% | $1.07B | vs FTRE |
| LMRILumexa Imaging Holdings Inc. | 10.59 | -1.12% | $1.02B | vs FTRE |
| CSTLCastle Biosciences Inc. | 33.00 | -1.08% | $1.01B | vs FTRE |
Indexes, lists and sector
Fortrea stock FAQ
What is Fortrea's stock price today?
FTRE last traded at $20.56 as of Oct 7, 4:00 PM EDT, down 1.06% on the day. Prices are delayed at least 15 minutes.
When is Fortrea's next earnings date?
Fortrea is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $0.23.
Who is Fortrea's CEO?
Mr. Anshul Thakral is the chief executive officer of Fortrea Holdings Inc., which has about 14,000 employees.
What is the FTRE 52-week high?
The 52-week high for FTRE is $23.51 and the 52-week low is $8.55. The stock is currently 12.5% below its high.